{"filing":{"accession_number":"0001104659-26-085061","cik":"0001708527","ticker":"ELUT","company_name":"ELUTIA INC.","form":"8-K","filing_date":"2026-07-20","report_date":null,"primary_document":"tm2620864d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1708527/000110465926085061/tm2620864d1_8k.htm"},"events":[{"id":18785,"run_id":16900,"accession_number":"0001104659-26-085061","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Elutia entered into a definitive Asset Purchase Agreement on July 16, 2026, to sell substantially all assets of its SimpliDerm Business (Women's Health segment) to Cellution Biologics for up to $11 million in cash and milestone payments, completing its strategic process and providing non-dilutive capital to support NXT-41x pipeline development.","company_name":"ELUTIA INC.","ticker":"ELUT","filing_date":"2026-07-20","form":"8-K","submitted_at":null,"items":[{"id":17697,"accession_number":"0001104659-26-085061","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Elutia entered into a definitive Asset Purchase Agreement on July 16, 2026, to sell substantially all assets of its SimpliDerm Business (its entire Women's Health segment) to Cellution Biologics for up to $11 million in cash and milestone payments. This is a material disposition of a significant business line that would affect a reasonable investor's assessment of the company's strategic direction, asset base, and capital structure. The transaction is explicitly disclosed under Item 1.01 (Entry into a Material Definitive Agreement) and represents a major strategic shift toward focusing on NXT-41x development.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:08:56.562526+00:00","company_name":"","ticker":null,"filing_date":""},{"id":17698,"accession_number":"0001104659-26-085061","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Elutia announced the signing of a definitive agreement to sell its SimpliDerm® business to Cellution Biologics for total consideration of up to $11 million ($8 million cash at closing plus up to $3 million in milestone payments). This is a material disposition of a business unit that would affect a reasonable investor's assessment of the company's capital structure, strategic focus, and financial position. The transaction is explicitly described as a divestiture that \"completes Elutia's previously announced strategic process\" and provides non-dilutive capital to support the company's NXT-41x pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:08:56.562526+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17697,"accession_number":"0001104659-26-085061","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Elutia entered into a definitive Asset Purchase Agreement on July 16, 2026, to sell substantially all assets of its SimpliDerm Business (its entire Women's Health segment) to Cellution Biologics for up to $11 million in cash and milestone payments. This is a material disposition of a significant business line that would affect a reasonable investor's assessment of the company's strategic direction, asset base, and capital structure. The transaction is explicitly disclosed under Item 1.01 (Entry into a Material Definitive Agreement) and represents a major strategic shift toward focusing on NXT-41x development.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:08:56.562526+00:00","company_name":"ELUTIA INC.","ticker":"ELUT","filing_date":"2026-07-20"},{"id":17698,"accession_number":"0001104659-26-085061","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Elutia announced the signing of a definitive agreement to sell its SimpliDerm® business to Cellution Biologics for total consideration of up to $11 million ($8 million cash at closing plus up to $3 million in milestone payments). This is a material disposition of a business unit that would affect a reasonable investor's assessment of the company's capital structure, strategic focus, and financial position. The transaction is explicitly described as a divestiture that \"completes Elutia's previously announced strategic process\" and provides non-dilutive capital to support the company's NXT-41x pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:08:56.562526+00:00","company_name":"ELUTIA INC.","ticker":"ELUT","filing_date":"2026-07-20"}]}